Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $14.00 price target on Altimmune (NASDAQ: ALT).The analyst commented, "48-week ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE